109820 — GENEMATRIX Balance Sheet
0.000.00%
- KR₩51bn
- KR₩51bn
- KR₩10bn
Annual balance sheet for GENEMATRIX, fiscal year end - December 31st, KRW millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | — | — | — | — | — |
| Source: | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts | ARS | Annual Audited Accounts |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Cash | |||||
| Cash and Equivalents | |||||
| Short Term Investments | |||||
| Cash and Short Term Investments | 12,212 | 12,479 | 4,798 | 2,135 | 1,828 |
| Net Total Accounts Receivable | |||||
| Net Total Receivables | 2,694 | 6,238 | 13,227 | 14,264 | 14,577 |
| Total Inventory | |||||
| Prepaid Expenses | |||||
| Total Other Current Assets | |||||
| Total Current Assets | 19,062 | 21,113 | 21,280 | 19,405 | 19,568 |
| Gross Property, Plant And Equipment | |||||
| Accumulated Depreciation | |||||
| Net Property, Plant And Equipment | 6,318 | 6,168 | 6,325 | 6,442 | 6,014 |
| Net Intangible Assets | |||||
| Long Term Investments | |||||
| Other Long Term Assets | |||||
| Total Assets | 38,168 | 39,532 | 31,902 | 31,354 | 28,458 |
| Accounts Payable | |||||
| Accrued Expenses | |||||
| Notes Payable / Short Term Debt | |||||
| Current Portion of Long Term Debt / Capital Leases | |||||
| Total Other Current Liabilities | |||||
| Total Current Liabilities | 4,082 | 5,343 | 5,006 | 4,519 | 4,704 |
| Capital Lease Obligations | |||||
| Total Long Term Debt | |||||
| Total Debt | |||||
| Total Other Liabilities | |||||
| Total Funded Status | |||||
| Total Liabilities | 4,775 | 7,211 | 7,717 | 8,206 | 9,231 |
| Common Stock | |||||
| Additional Paid In Capital | |||||
| Retained Earnings (Accumulated Deficit) | |||||
| Treasury Stock | |||||
| Unrealized Gain / Loss | |||||
| Other Equity | |||||
| Total Equity | 33,393 | 32,321 | 24,186 | 23,148 | 19,227 |
| Total Liabilities & Shareholders' Equity | 38,168 | 39,532 | 31,902 | 31,354 | 28,458 |
| Total Common Shares Outstanding |